Publications by Dr John Anderson - ePrints

Browsing publications by Dr John Anderson.

Newcastle Authors	Title	Year
Dr Karen Barker Philip Berry Professor Gareth Veal Dr John Anderson	In vivo Modelling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis	2019
Professor Colin Rees Dr John Anderson Professor Matt Rutter	Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative	2017
Dr Christine Challen Dr John Anderson Professor Zofia Chrzanowska-Lightowlers Professor Robert Lightowlers Professor John Lunec et al.	Recombinant human MDM2 oncoprotein shows sequence composition selectivity for binding to both RNA and DNA	2012
Dr Rachel Crossland Professor Stephen Proctor Dr Brian Angus Dr Stephen Crosier Dr John Anderson et al.	A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines	2010
Dr Rachel Crossland Dr John Anderson Dr Brian Angus Professor Stephen Proctor Dr Stephen Crosier et al.	A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines	2010
Dr Rachel Crossland Dr John Anderson Dr Brian Angus Professor Stephen Proctor Dr Stephen Crosier et al.	A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines	2010
Dr John Anderson Lynne Overman Dr Katrina Wood Professor Stephen Proctor Dr Stephen Crosier et al.	Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics	2009
Dr Tryfonia Mainou-Fowler Lynne Overman Dr Katrina Wood Dr Brian Angus Professor Stephen Proctor et al.	A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2	2008
Dr Tryfonia Mainou-Fowler Professor Stephen Proctor Dr John Anderson	CD31 density is a new risk factor for patients with B-cell chronic lymphocytic leukaemia	2008
Dr Tryfonia Mainou-Fowler Dr John Anderson Professor Stephen Proctor	CD31 density is a novel risk factor for patients with B-cell chronic lymphocytic leukaemia	2008
Seamus Kelly Dr John Anderson Dr Brian Angus Dr Christine Challen Professor John Lunec et al.	The predictive value of p53 and p33ING1b in patients with Dukes'C colorectal cancer	2008
Dr Xiaomei Lu Dr Simon Baudouin Professor James Gillespie Dr John Anderson Professor Anne Dickinson et al.	A comparison of CFU-GM, BFU-E and endothelial progenitor cells using ex vivo expansion of selected cord blood CD133⁺ and CD34⁺ cells	2007
Dr Xiaomei Lu Dr Simon Baudouin Professor James Gillespie Dr John Anderson Professor Anne Dickinson et al.	A comparison of CFU-GM, BFU-E and endothelial progenitor cells using ex vivo expansion of selected cord blood CD133+ and CD34+ cells	2007
Dr Tryfonia Mainou-Fowler Lynne Overman Dr Katrina Wood Dr Stephen Crosier Dr Brian Angus et al.	A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2	2007
Dr Rachel Crossland Dr Christine Challen Dr Bridget Wilkins Dr Stephen Crosier Dr John Anderson et al.	Definitive identification of the Val617Phe mutation in myeloproliferative disorders using Real Time PCR utilising Roche Lightcycler/hybriprobe technology	2007
Dr John Anderson Professor Robert Lightowlers Professor John Lunec	DNA and RNA Binding of a Bacterially Expressed Human MDM2 Onco-protein	2007
Dr John Anderson Dr Christine Challen Dr Stephen Crosier Professor John Lunec	MDM2 RNA binding is blocked by novel monoclonal antibody h-MDM2-F4-14	2007
Dr John Anderson Dr Stephen Crosier Lynne Overman Dr Tryfonia Mainou-Fowler Dr Sarah Fordham et al.	Survivin in diffuse large B cell lymphoma: Evaluation as a prognostic marker	2005
Dr John Anderson Dr Stephen Crosier Dr Jyotsna Shrimankar Professor John Lunec Dr Brian Angus et al.	Downregulation of nuclear expression of the p33^ING1binhibitor of growth protein in invasive carcinoma of the breast	2003
Dr Stephen Crosier Dr Katrina Wood Dr Philip Taylor Professor Stephen Proctor Dr Brian Angus et al.	IAP survivin in diffuse large B cell lymphoma: Evaluation as a prognostic marker	2003
Professor David Neal Philip Powell Monica Smith Dr John Anderson Barbara Hattrick et al.	Prostate testing for cancer and treatment (ProtecT) feasibility study	2003
Dr John Anderson Professor John Lunec Dr Brian Angus	The role of the tumour suppressor p33ING1b in human neoplasia	2003
Andrew Lodge Dr John Anderson Dr Beate Haugk Dr Brian Angus	Type 1 growth factor receptor expression in node positive breast cancer: Adverse prognostic significance of c-erbB-4	2003
Dr Brian Angus Professor John Lunec Dr Stephen Crosier Andrew Lodge Dr John Anderson et al.	Comparative assessment expression of the inhibitor of growth 1 gene (ING1) in normal and neoplastic tissues	2002
Dr John Anderson	GN1 anti-p33^ING1b tumor suppressor	2002
Dr John Anderson	GN2 anti-p33^ING1b tumor suppressor	2002
Dr John Anderson Dr Katrina Wood Professor John Lunec Dr Andrew Hall Dr Michael Reid et al.	Loss of nuclear expression of the p33ING1b inhibitor of growth protein in childhood acute lymphoblastic leukaemia	2002
Dr John Anderson Dr Marie Mathers Dr Niamh Leonard Dr Stephen Crosier Professor John Lunec et al.	Nuclear to cytoplasmic compartment shift of the p33ING1b tumour suppressor protein is associated with malignancy in melanocytic lesions	2002
Seamus Kelly Dr John Anderson Dr Brian Angus Professor John Lunec	p33/ING1 nuclear expression and TP53 gene mutation in colorectal cancer and their association with clinical outcome	2002
Dr John Anderson Dr Stephen Crosier Dr Jyotsna Shrimankar Professor John Lunec Dr Brian Angus et al.	p33^ING1b tumour suppressor immunohistochemical expression in invasive breast carcinomas	2002
Seamus Kelly Dr John Anderson Dr Brian Angus Professor John Lunec	TP53 and p33(Ing1) are co-determinants of prognosis in colorectal cancer	2002
Dr Stephen Crosier Dr Brian Angus Dr John Anderson	Use of transgenomic wave and denaturing gel electrophoresis increases the sensitivity of FR3A-FR4 PCR detection of B-cell clonality	2002
Professor John Lunec Seamus Kelly Dr John Anderson Dr Brian Angus	Expression of p33/ING1 gene products in colorectal cancer and its correlation with survival	2001
Dr John Anderson Professor John Lunec Dr Andrew Hall Dr Michael Reid Dr Brian Angus et al.	p33(ING1b) tumour suppresser protein expression in childhood acute lymphoblastic leukaemia by immunohistochemistry	2001
Dr Stephen Crosier Dr John Anderson Dr Marie Mathers Dr Niamh Leonard Dr Stephen Crosier et al.	p33(ING1b) tumour suppresser protein expression in melanocytic lesions, an immunohistochemical study of 67 cases	2001
Seamus Kelly Professor John Lunec Dr John Anderson Dr Brian Angus	p33/ING1 nuclear expression in colorectal cancer and its correlation with metastasis and survival	2001
Dr John Anderson Dr Stephen Crosier Professor John Lunec Dr Brian Angus	p33^ING1b tumour suppresser protein expression in thyroid lesions determined by immunohistochemistry	2001
Dr Dina Tiniakos Dr John Anderson	c-fos oncogene expression in human breast carcinoma	2000
Andrew Lodge Dr John Anderson Dr Beate Haugk Dr Brian Angus	Expression of topoisomerase III alpha in normal and neoplastic tissues determined by immunohistochemistry using a novel monoclonal antibody	2000
Andrew Lodge Dr John Anderson Dr Beate Haugk Dr Brian Angus	Expression of topoisomerase IIIα in normal and neoplastic tissues determined by immunohistochemistry using a novel monoclonal antibody	2000
Dr Brian Angus Professor John Lunec Dr John Anderson	Monoclonal antibodies raised to products of the ING1 tumour suppressor gene locus.	2000
Andrew Lodge Dr John Anderson Dr Brian Angus	Pixel-based image cytometry for quantification of nuclear antigen expression using Adobe Photoshop	2000
Dr Dina Tiniakos Dr John Anderson	Production and characterization of monoclonal antibodies to the human c-fos oncoprotein effective an routinely-processed tissues	2000
Dr John Anderson Dr Brian Angus Professor John Lunec	Sequencing of ING1 tumour suppressor gene cDNAs generated from mRNA recovered from normal and neoplastic cell lines.	2000
Andrew Lodge Dr John Anderson Dr Beate Haugk Dr Brian Angus	Type 1 growth factor receptor and topoisomerase expression in breast cancer: Adverse prognostic significance of c-erbB-4	2000
Dr Craig Dixon Dr Simon Sinclair Dr Fraser Charlton Dr John Anderson Professor Peter Farr et al.	Diagnosis of mycosis fungoides using histological evaluation, immunophenotyping and molecular analysis in formalin-fixed, parafin-embedded tissue	1999
Andrew Lodge Dr Andrew Hall Dr Katrina Wood Dr John Anderson Dr Brian Angus et al.	NCL-CD10-270: A new monoclonal antibody recognizing CD10 in paraffin- embedded tissue	1999
Andrew Lodge Dr Andrew Hall Dr John Anderson Dr Michael Reid Dr Brian Angus et al.	A study of the prognostic significance of topoisomerase IIα in childhood acute lymphoblastic Leukaemia	1998
Dr Katrina Wood Dr Keith Mitchell Professor Stephen Proctor Dr Fergus Jack Helen Bell et al.	Development of new monoclonal antibodies recognising CD5, CD10, CD23, cyclin D1 and Ki67 in paraffin sections, and determination of their value in diagnosis of small B cell lymphoma	1998
Dr John Anderson Dr William Cowan William Cunliffe Dr Brian Angus	ER-CARD: a more sensitive method for detection of oestrogen receptor by immunohistochemistry	1998
Dr John Anderson Professor Thomas Lennard Dr Brian Angus	A novel quantitative immunoassay system for p53 using antibodies selected for optimum designation of p53 status	1997
Dr Mark Egan Dr John Anderson Dr William Cowan Dr Brian Angus	Optimised determination of vascular invasion in breast cancer by immunohistochemistry for CD31: production of a novel monoclonal antibody and comparison with conventional assessment.	1997
Professor Alan Calvert Dr John Anderson Professor David Neal Professor John Lunec	Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer	1996
Dr John Anderson Dr Brian Angus	Determination of the clinical significance of cyclin a expression in human breast cancer using a novel monoclonal antibody	1996
Dr John Anderson Dr Brian Angus Professor Thomas Lennard	p53 protein as a prognostic indicator in breast carcinoma: A comparison of four antibodies for immunohistochemistry	1996
Dr John Anderson Professor Thomas Lennard Dr Brian Angus	Retinoblastoma protein in human breast carcinoma: Immunohistochemical study using a new monoclonal antibody effective on routinely processed tissues	1996
Dr John Anderson Dr Brian Angus Professor Thomas Lennard	Determination of the prognostic value of cyclin D1 overexpression in breast cancer	1995
Dr Dina Tiniakos Dr John Anderson Dr Mary Robinson Professor David Neal	c-jun oncogene expression in transitional cell carcinoma of the urinary bladder	1994
Dr John Anderson Dr Christopher Wright Dr Brian Angus	NDP-K/nm23 expression in human breast cancer in relation to relapse, survival, and other prognostic factors: an immunohistochemical study	1994
Dr John Anderson Emeritus Professor Geoffrey Toms Dr Ronald Scott	Recognition of respiratory syncytial (RS) virus proteins by human and BALB/C CD4+ lymphocytes	1991
Dr John Anderson Jean Norden Dr David Saunders Emeritus Professor Geoffrey Toms Dr Ronald Scott et al.	Analysis of the local and systemic immune responses induced in BALB/c mice by experimental respiratory syncytial virus infection	1990
Dr John Anderson Emeritus Professor Geoffrey Toms Dr Ronald Scott	Natural killer cell response to respiratory syncytial virus in the Balb/c mouse model	1989
Dr Edward Routledge Dr Tony Samson Dr Ronald Scott Dr John Anderson Emeritus Professor Geoffrey Toms et al.	The purification of four respiratory syncytial virus proteins and their evaluation as protective agents against experimental infection in BALB/c mice	1988